CBP Baltimore Field Office Seizes nearly 59,000 Counterfeit COVID-19 Facemasks and other Test Kits and Medications
BALTIMORE – U.S. Customs and Border Protection (CBP) officers throughout the Mid-Atlantic region continue to seize caches of counterfeit or unapproved COVID-19 medications, facemasks and test kits that arrived in express consignment during the previous six weeks.
Topping the seizures are 58,846 facemasks that violated trademark protections of numerous brands, including designer consumer brands, sports teams, vehicle manufacturers, cartoon characters and others. Collectively, the facemasks would have had a manufacturer’s suggested retail price of about $2,553,000, if authentic.
CBP officers at the Port of Pittsburgh seized the largest single shipment of these counterfeit facemasks – 17,220 facemasks – on September 1, with an MSRP of $990,320. This shipment arrived from Hong Kong and was destined to an address in Allegheny County, Pa.
Oftentimes, counterfeit products are manufactured in unregulated facilities with substandard materials that could potentially harm American consumers.
“The volume of counterfeit COVID-19 facemasks is astonishing and further evidence that predatory scammers will take advantage of an international pandemic to line their greedy pockets by peddling illicit and potentially dangerous products as legitimate COVID-19 personal protective equipment,” said Casey Durst, Director of Field Operations for CBP’s Baltimore Field Office. “Customs and Border Protection officers remain committed to working with our consumer safety partners and protecting American consumers by intercepting these potentially harmful shipments.”
Since August 13, CBP officers at the Area Ports of Philadelphia, Baltimore and Washington, and the Ports of Harrisburg, Pa., Pittsburgh and Wilmington, Del., have seized:
- 58,846 counterfeit facemasks during 21 seizures;
- 916 tablets of COVID-related medications during two seizures; and
- 134 COVID-19 test kits and antibody tests during six seizures
These test kits and medications are not on the current Emergency Use Authorization List nor are the manufacturers on the list of firms who have provided compliance notification to the FDA. As such, the products are inadmissible to the United States for violating the Federal Food, Drug, and Cosmetic Act.
CBP is withholding specific details of individual seizures as many cases remain under investigation.
The products arrived from Finland, Hong Kong, Nigeria, Philippines, Poland, South Africa, Spain, Thailand, United Arab Emirates, United Kingdom, and Vietnam. The parcels were destined to addresses in Florida, North Carolina, Pennsylvania, and Virginia,
Read previous notifications of CBP’s Baltimore Field Office COVID-related product seizures at:
- CBP announces 11 COVID-related products seizure August 7;
- CBP announces 18 COVID-related product seizures on June 5; and
- CBP announces 18 COVID-related product seizures on May 11.
CBP's border security mission is led at ports of entry by CBP officers from the Office of Field Operations. Please visit CBP Ports of Entry to learn more about how CBP’s Office of Field Operations secures our nation’s borders. Learn more about CBP at www.CBP.gov.
U.S. Customs and Border Protection is the unified border agency within the Department of Homeland Security charged with the management, control and protection of our nation's borders at and between official ports of entry. CBP is charged with securing the borders of the United States while enforcing hundreds of laws and facilitating lawful trade and travel.